Author, year	Group	Cases, n	Age, years	Sex, M:F	Duration of treatment WK	Baseline MADRS score^a	Doses VTX^b	Study location	Entry score by MADRS
Boulener et al. 2014	Treatment	151	46.2 ± 13.4	60:91	8	31.2 ± 3.4	15, 20 mg	Europe	≥26
Boulener et al. 2014	Placebo	158	48.1 ± 13.1	48:110	8	31.5 ± 3.6	15, 20 mg	Europe	≥26
Mahableshwarkar et al. 2013	Treatment	154	42.8 ± 12.40	40:114	8	32.0 ± 4.36	15, 20 mg	Usa	≥26
Mahableshwarkar et al. 2013	Placebo	161	42.4 ± 12.55	45:116	8	31.6 ± 4.18	15, 20 mg	Usa	≥26
Jacobsen et al. 2013	Treatment	150	43.1 ± 13.09	43:107	8	32.4 ± 4.30	10, 20 mg	Usa	≥26
Jacobsen et al. 2013	Placebo	157	42.3 ± 11.61	47:110	8	32.0 ± 3.99	10, 20 mg	Usa	≥26
Trial NCT01255787 2014	Treatment	154	44.0 ± 11.79	61:93	8	31.7 ± 3.73	5, 10, 20 mg	Europe-Asia	≥26
Trial NCT01255787 2014	Placebo	152	43.6 ± 11.57	61:91	8	31.6 ± 3.56	5, 10, 20 mg	Europe-Asia	≥26